Epigenetic IVD Tests for Personalized Precision Medicine in Cancer

• Main Authors: Jesús Beltrán-García, Rebeca Osca-Verdegal, Salvador Mena-Mollá, José Luis García-Giménez
• Format: Article
• Language: English
• Published: Frontiers Media S.A. 2019-06-01
• Series: Frontiers in Genetics
• Subjects: precision medicine; epigenetic biomarker; In Vitro Diagnostic (IVD); DNA methylation; miRNA; cfDNA
• Online Access: https://www.frontiersin.org/article/10.3389/fgene.2019.00621/full

Epigenetic alterations play a key role in the initiation and progression of cancer. Therefore, it is possible to use epigenetic marks as biomarkers for predictive and precision medicine in cancer. Precision medicine is poised to impact clinical practice, patients, and healthcare systems. The objective of this review is to provide an overview of the epigenetic testing landscape in cancer by examining commercially available epigenetic-based in vitro diagnostic tests for colon, breast, cervical, glioblastoma, lung cancers, and for cancers of unknown origin. We compile current commercial epigenetic tests based on epigenetic biomarkers (i.e., DNA methylation, miRNAs, and histones) that can actually be implemented into clinical practice.